Stay up to date on our announcements, media coverage, and resources.

Press releases and statements

Our latest company updates, product launches, leadership announcements, and public statements.

Recent highlights

Celltrion to Present New Analyses of OMLYCLO® (omalizumab-igec) in Chronic Spontaneous Urticaria at ACAAI 2026

Read more

Celltrion to Present New Analyses of ZYMFENTRA® (infliximab-dyyb) in Crohn's Disease and Ulcerative Colitis at ACG 2026

Read more

Celltrion in the News

Celltrion USA's adalimumab-aaty biosimilar to HUMIRA® now available at low wholesale acquisition cost

Adalimumab-aaty will be priced at an 85% discount to HUMIRA® (adalimumab) Branded and unbranded versions of Celltrion USA’s adalimumab biosimilar help provide more affordable options for patients JERSEY CITY, N.J., May 9, 2024 /PRNewswire/ — Celltrion USA announced today that adalimumab-aaty, the company’s high-concentration (100 mg/mL) and citrate-free formulation biosimilar to HUMIRA ® (adalimumab), is now available at a low wholesale acquisition cost (WAC). Adalimumab-aaty […]
Read more

ZYMFENTRA™(infliximab-dyyb), the first and only FDA-approved subcutaneous infliximab, now commercially available in the U.S.

ZYMFENTRA™ is the first FDA-approved subcutaneous infliximab for the treatment of moderately to severely active ulcerative colitis and moderately to severely active Crohn’s disease ZYMFENTRA™ is commercially available across the U.S. on March 15, 2024 JERSEY CITY, N.J., March 17, 2024 /PRNewswire/ — Celltrion USA announced today the availability of a ZYMFENTRA™ (infliximab-dyyb), a subcutaneous (SC) formulation of infliximab.[1]  ZYMFENTRA is the first and […]
Read more

Celltrion completes submission of Biologics License Application (BLA) to U.S. FDA for CT-P39, an interchangeable biosimilar candidate of XOLAIR® (omalizumab)

The BLA for CT-P39 was based on totality of evidence including results from Phase III data demonstrating comparable efficacy and safety profile with the reference product XOLAIR® (omalizumab) in patients with chronic spontaneous urticaria   JERSEY CITY, N.J., March 10, 2024 /PRNewswire/ — Celltrion today announced that the company has submitted a Biologics License Application (BLA) for CT-P39, […]
Read more

Celltrion USA completes submission of Biologics License Application for CT-P47, a biosimilar candidate of ACTEMRA® (tocilizumab)

The Biologics License Application for CT-P47 was based on Phase III data comparing CT-P47 to the reference product ACTEMRA® (tocilizumab)   JERSEY CITY, N.J., Jan. 28, 2024 /PRNewswire/ — Celltrion USA today announced the submission of Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for CT-P47, a biosimilar candidate of the reference product […]
Read more

Celltrion USA announces distribution and incorporation of YUFLYMA® (adalimumab-aaty), a Humira® biosimilar, to CarePartners Specialty Pharmacy Cost Savings Programs

Celltrion USA announces distribution and incorporation of YUFLYMA® (adalimumab-aaty), a Humira® biosimilar, to CarePartners Specialty Pharmacy Cost Savings Programs YUFLYMA® (adalimumab-aaty) was first approved by the Food and Drug Administration on May 23, 2023 and became commercially available in the U.S. on July 2, 2023 The treatment will be available on CarePartners Specialty Pharmacy Program in late October […]
Read more

Celltrion USA Announces U.S. FDA Approval of ZYMFENTRA™ (infliximab-dyyb), the First and Only Subcutaneous infliximab, for the Treatment of People With Inflammatory Bowel Disease

Celltrion USA Announces U.S. FDA Approval of ZYMFENTRA™ (infliximab-dyyb), the First and Only Subcutaneous infliximab, for the Treatment of People With Inflammatory Bowel Disease ZYMFENTRA™ is the first and only FDA-approved subcutaneous (SC) formulation of infliximab approved for the maintenance treatment of adult patients with moderately to severely active ulcerative colitis and Crohn’s disease Novel subcutaneous administration […]
Read more

Media asset library

Assets and resources for journalists, partners, and stakeholders.

Access assets